Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133920 | 0.89 | ADORA1 (0.42) | ADORA1ADORA2ACYP1A2 | |
| SCHEMBL6134475 | 0.86 | ADORA1 (0.41) | ADORA1ADORA2ACYP1A2 | |
| SCHEMBL6133379 | 0.86 | ADORA1 (0.58) | ADORA1ADORA2ACYP1A2CCNT1CCNA2 | |
| SCHEMBL6133302 | 0.85 | CYP1A2 (0.54) | ADORA1ADORA2ACYP1A2 | |
| SCHEMBL6134045 | 0.85 | RPS6KA3 (0.44) | ADORA1ADORA2ACYP1A2 | |
| SCHEMBL6134308 | 0.83 | ADORA2A (0.61) | ADORA1ADORA2AADORA2B | |
| SCHEMBL6133404 | 0.82 | CYP1A2 (0.37) | ADORA1ADORA2ACYP1A2 | |
| SCHEMBL6133337 | 0.81 | HSP90AA1 (0.48) | ADORA1ADORA2ACYP1A2 | |
| SCHEMBL6133477 | 0.80 | ADORA1 (0.55) | ADORA1ADORA2ADHFRNOTUM | |
| SCHEMBL1554448 | 0.80 | ADORA1 (0.52) | ADORA1ADORA2ACCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885CYP1A2 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.